Shengjin Jin

My name is Shengjin Jin, Senior Director of Gene Therapy Drug Substance MS&T group at Sarepta. I have been with Sarepta for 5+ years, leading the drug substance process tech transfer and commercialization of Sarepta’s first gene therapy program, SRP-9001/Elevidys, for the treatment of Duchenne muscular dystrophy. Prior to joining Sarepta, I spent ten years at Shire/Takeda, started as a downstream MS&T lab lead, grew into the role of the Head of the Massachusetts site-based MS&T team, supported the commercial manufacturing of three enzyme replacement therapy products. Before that, I was a scientist in the Process Development department at Immunogen, aided the development of the antibody conjugate of Herceptin, Kadcyla, a commercial product for breast cancer treatment. Trained in Biochemistry and Molecular Virology, I earned a BS Degree from Beijing Normal University and MS Degrees from Chinese Academy of Preventive Medicine and Boston University.